Table 1.

Baseline characteristics of patients who underwent Roux-en-Y gastric bypass or sleeve gastrectomy procedure from 36 health systems participating in the PCORnet Bariatric Study

Variablea	Roux-en-Y gastric bypass		Sleeve gastrectomy
	Number	Proportion	Number	Proportion
Total	23,963	100.0	19,147	100.0
Age
20–44	11,059	46.2	9,547	49.9
45–64	11,728	48.9	8,648	45.2
65–80	1,176	4.9	952	5.0
Male sex	4,701	19.6	3,748	19.6
Race
White	16,995	70.8	10,970	57.3
Black	3,468	14.5	4,618	24.1
Other	3,540	14.8	3,559	18.6
Hispanic ethnicity	3,813	15.9	4,624	24.2
Year of procedure
2005–2009	1,937	8.1	424	2.2
2010	3,487	14.6	1,195	6.2
2011	4,767	19.9	3,138	16.4
2012	6,101	25.5	4,011	21.0
2013	3,850	16.1	4,771	24.9
2014	3,315	13.9	4,908	25.6
2015	506	2.1	700	3.7
Comorbidity score (SD)	−0.01	0.9	−0.04	0.9
Baseline weight (SD)	280.37	57.0	274.86	57.6
Baseline weight proximityb (SD)	−21.64	35.3	−14.60	31.2
Days of hospitalization (SD)	0.60	8.0	0.49	6.6
Smoking	2,278	9.5	1,605	8.4
Diagnosis of
Anxiety	5,404	22.6	4,080	21.3
Deep vein thrombosis	181	0.8	150	0.8
Depression	8,150	34.0	5,540	28.9
Diabetes	10,608	44.3	5,677	29.7
Dyslipidemia	12,663	52.8	8,868	46.3
Eating disorder	3,833	16.0	1,168	6.1
GERD	11,196	46.7	6,917	36.1
Hypertension	15,452	64.5	10,798	56.4
Infertility	172	0.7	159	0.8
Kidney disease	2,172	9.1	1,469	8.0
NAFLD	6,853	28.6	3,231	16.9
Osteoarthritis	461	1.9	337	1.8
PCOS	1,281	5.4	919	4.8
Psychosis	1,240	5.2	701	3.7
Pulmonary embolism	320	1.3	225	1.2
Sleep apnea	13,116	54.7	8,255	43.1
Substance use disorder	522	2.2	462	2.4

Notes:

^aMeasured in the year prior to the surgery unless otherwise specified;

^bnumber of days between baseline weight measurement and index procedure.

Abbreviations: GERD, gastroesophageal reflux disease; NAFLD, nonalcoholic fatty liver disease; PCORnet, National Patient-Centered Clinical Research Network; PCOS, polycystic ovarian syndrome.